Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

PIK3CA testing in HR+/HER2- metastatic breast cancer: assessing pathology laboratories capacity and needs.

Pathologica - 1 Dec 2025

Mane Eltjona, Cursano Giulia, Venetis Konstantinos, Frascarelli Chiara, Pepe Francesco, Nacchio Mariantonia, Palumbo Lucia, Pisapia Pasquale, De Camilli Elisa, Castellano Isabella, Cerbelli Bruna, Costarelli Leopoldo, d'Amati Giulia, Rizzo Antonio, Santinelli Alfredo, Scatena Cristian, Criscitiello Carmen, De Angelis Carmine, Dieci Maria Vittoria, Troncone Giancarlo, Curigliano Giuseppe, Viale Giuseppe, Guerini-Rocco Elena, Malapelle Umberto, Fusco Nicola

Abstract excerpt

The management of hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) relies on molecular testing to inform treatment decisions. PIK3CA mutations, present in ~40% of cases, represent a key predictive biomarker for PI3K-pathway-targeted therapies. Despite its clinical relevance, PIK3CA testing continues to face challenges related to laboratory organization, standardization, and...

Topics

Humans
Class I Phosphatidylinositol 3-Kinases
Breast Neoplasms
Female
Erb-b2 Receptor Tyrosine Kinases
Biomarkers, Tumor
Cross-Sectional Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Italy

Mutation

Receptors, Progesterone

Laboratories, Clinical

Receptors, Estrogen

Source

Open in PubMed Open full text

Identifiers

PMID: 41954342
DOI: 10.32074/1591-951X-1603
PMCID: PMC13094337

Genes

PIK3CA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PIK3CA testing in HR+/HER2- metastatic breast cancer: assessing pathology laboratories capacity and needs.PMID 41954342Read ↗

PIK3CA testing in hormone receptor-positive/HER2-negative metastatic breast cancer: real-world data from Italian molecular pathology laboratories.Semantic proximity Read ↗

Analytical Performance of Next-Generation Sequencing and RT-PCR on Formalin-Fixed Paraffin-Embedded Tumor Tissues for PIK3CA Testing in HR+/HER2− Breast CancerSemantic proximity Read ↗

Integrating PIK3CA Testing into Clinical Practice for Advanced HR+/HER2- Breast Cancer: An Expert Consensus.Semantic proximity Read ↗

Quality-Assured Analysis of PIK3CA Mutations in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Tissue.Semantic proximity Read ↗

Proficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissue.Semantic proximity Read ↗

The Multi-Omic Transformation of Breast Cancer Diagnostics: A Comprehensive Review of the Transition from Immunohistochemistry to Liquid Biopsy and Next-Generation SequencingSemantic proximity Read ↗

Molecular Analysis of PIK3CA in Metastatic Hormone Receptor-Positive Breast Cancer in Chile: Clinical and Pathological Insights.Semantic proximity Read ↗

Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients.Semantic proximity Read ↗

What Do German Molecular Tumor Boards Recommend in Patients with PIK3CA-Mutated Tumors? Launch and First Results from the German Transsectoral Molecular Tumor Board Exchange Platform Deutschland.Semantic proximity Read ↗

NGS mutational status on first diagnostic tissue, liquid biopsy and mastectomy in G2-G3 breast cancer.Semantic proximity Read ↗

[What's new liquid biopsy-PIK3CA testing in breast cancer].Semantic proximity Read ↗

Tumor mutation burden testing: a survey of the International Quality Network for Pathology (IQN Path).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.